Q3 2014 · —
Revenue$306.58M$306.58M +32.1% vs Q3 2013+5.3% vs Q2 2014
Net Income$25.77M$25.77M −65.8% vs Q3 2013−41.0% vs Q2 2014
EPS Diluted$0.41$0.41 −66.7% vs Q3 2013−41.4% vs Q2 2014
Gross Profit$277,413,000+34.6%
Operating Income$58,036,000−42.3%
Operating Cash Flowderived$129,697,000−0.8%
Free Cash Flowderived$121,558,000−5.5%
Margins · derived
Gross margin90.5%+1.7 pt vs Q3 2013
Operating margin18.9%−24.4 pt vs Q3 2013
Net margin8.4%−24.1 pt vs Q3 2013
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2014 | Q3 2013 | Q3 2012 | Q3 2011 |
|---|---|---|---|---|
| Revenue | $306.58M | $232.16M | $175.52M | $73.29M |
| Net Income | $25.77M | $75.41M | $33.21M | $32.48M |
| EPS Diluted | $0.41 | $1.23 | $0.55 | $0.69 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR